This analysis evaluates Insmed's commercial and late-stage clinical portfolio for suitability with Ada Patient Finder. Of five drugs assessed, BRINSUPRI (bronchiectasis) represents the highest-value opportunity, with 300,000-500,000 undiagnosed US patients addressable via Ada's symptom checker.
| Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity (Annual) |
|---|---|---|---|---|
| BRINSUPRI Bronchiectasis |
1 | 9/10 | 300,000-500,000 | $17.5M-$51.3M (5% penetration) |
| ARIKAYCE Refractory MAC |
2 | 7/10 | 30,000-40,000 total MAC 600-800 refractory |
$208K-$821K (5% penetration) |
| TPIP PH-ILD / PAH |
2 | 6/10 | 65,000-120,000 | $2.58M-$7.10M (post-approval 2028+) |
| INS1148 Asthma / ILD |
2 / 3 | 7/10 (asthma) 5/10 (ILD) |
1.5M-1.9M undertreated (asthma) 250K undiagnosed (ILD) |
$5.96M-$11.8M (post-approval 2030+) |
| INS1201 DMD Gene Therapy |
3 | 3/10 | ~1,000 | $5.02M-$8.86M (post-approval 2029+) |
Indication: Non-Cystic Fibrosis Bronchiectasis
If Ada surfaces 5% of undiagnosed pool (13,500-22,500 patients annually):
Symptoms: Chronic daily cough with copious purulent sputum, shortness of breath, wheezing, fatigue, recurrent respiratory infections (≥3/year), hemoptysis (advanced cases)
Diagnostic Pathway: Ada flags "chronic productive cough + recurrent infections despite antibiotics" → prompts HRCT referral → confirmed bronchiectasis (broncho-arterial ratio >1)
Treatment Duration: Lifelong (irreversible structural lung damage)
Bronchiectasis affects an estimated 700,000-1 million Americans, yet only 350,000-500,000 are diagnosed, leaving 300,000-500,000 patients (30-50% of true prevalence) unidentified due to 3-7 year diagnostic delays and HRCT underutilization. These patients suffer chronic productive cough, recurrent respiratory infections, and progressive lung damage while misdiagnosed as chronic bronchitis or COPD in primary care.
Ada's symptom assessment AI is purpose-built to surface bronchiectasis: chronic cough (>8 weeks), copious purulent sputum, and ≥3 annual exacerbations are highly specific indicators that Ada captures in routine respiratory assessments. By flagging high-risk individuals and prompting HRCT referrals, Ada can accelerate diagnosis by 1-3 years, immediately expanding the pool of BRINSUPRI-eligible patients.
If Ada surfaces just 5% of the undiagnosed pool (13,500-22,500 patients annually), Insmed gains $594M-$990M in incremental annual revenue—representing 50-80% of BRINSUPRI's 2026 guidance (≥$1B).
With BRINSUPRI's first-mover advantage (3-5 years before competitors) and Insmed's explicit focus on patient identification as a key growth driver, Ada Patient Finder represents the highest-value strategic partnership in Insmed's portfolio.
Indication: Refractory MAC Lung Disease
Ada accelerates MAC diagnosis by 6-12 months, expanding diagnosed pool. 20% progress to refractory MAC (ARIKAYCE-eligible).
Symptoms: Chronic productive cough, fatigue, shortness of breath, low-grade fever/night sweats, weight loss
Ada's Role: Flags chronic respiratory symptoms unresponsive to standard treatment → prompts sputum culture testing → accelerates MAC diagnosis by 6-12 months
Treatment Duration: 12-18 months post-culture conversion
Phase 3 trial results expected: If positive, ARIKAYCE label expands from refractory MAC to newly diagnosed MAC (4x larger market: 76,000 vs 15,000-20,000). This would upgrade ARIKAYCE to Tier 1 opportunity.
MAC lung disease affects ~76,000 diagnosed Americans, with 30,000-40,000 additional cases undiagnosed due to 2-5 year diagnostic delays. Ada's respiratory symptom assessment can accelerate diagnosis by 6-12 months, expanding the pool of patients progressing to refractory MAC (20% of diagnosed cases) who become eligible for ARIKAYCE. With ENCORE trial results (March/April 2026) poised to expand ARIKAYCE's label to newly diagnosed MAC, Ada Patient Finder represents a strategic partner to maximize market penetration across a 4x larger addressable population.
Indication: Pulmonary Hypertension (PH-ILD and PAH)
Symptoms: Dyspnea on exertion (hallmark), fatigue, chest pain, syncope/dizziness, peripheral edema, palpitations
Ada's Role: Flags "unexplained dyspnea + exertional limitations + syncope/edema" → prompts echocardiography → accelerates PH diagnosis by 6-12 months. Particularly effective for targeting ILD patients with worsening symptoms.
Treatment Duration: Lifelong
Pulmonary hypertension affects 15,000-140,000 Americans, with PH-ILD particularly under-recognized (85-90% underdiagnosis). Ada's symptom assessment can flag high-risk individuals, especially ILD patients experiencing worsening dyspnea, prompting PH screening. TPIP's once-daily convenience differentiates from existing therapies. If approved (2028), TPIP addresses 10,000-25,000 diagnosed patients, with Ada expanding this pool by 10-20% through accelerated diagnosis. Partnership discussions ideal post-Phase 3 data readouts (2027).
Indication: Moderate-to-Severe Asthma and ILD
Asthma Symptoms: Wheezing, shortness of breath, chest tightness, nocturnal cough, frequent exacerbations (≥2/year)
Ada's Role (Asthma): Identifies inadequate control via exacerbation frequency, nocturnal symptoms, daily inhaler use patterns → prompts biologic evaluation
ILD Symptoms: Progressive dyspnea, dry cough, fatigue
Recommendation: Monitor Phase 2 progress; partnership discussions premature until 2027-2028 data readouts. Competitive asthma biologic market (Dupixent, Xolair, Nucala) limits differentiation risk.
Indication: Duchenne Muscular Dystrophy
Recommendation: Deprioritize. Newborn screening expansion reduces Ada's value proposition. Monitor but no active partnership discussions.
Action: Partner with Insmed on BRINSUPRI bronchiectasis patient finding.
Action: Engage Insmed on ARIKAYCE ENCORE trial results (March/April 2026).
Rationale: If positive, ARIKAYCE label expands to newly diagnosed MAC (4x larger market). Partnership timing ideal around ENCORE readout.
Action: Monitor TPIP Phase 3 data readouts (2027).
Rationale: PH-ILD massive underdiagnosis (85-90%); first-in-class opportunity. If Phase 3 successful, initiate partnership discussions for post-approval patient finding (2028+ launch).
Action: Monitor but no active partnership discussions.
| Metric | Finding |
|---|---|
| Highest Fit Score | BRINSUPRI (9/10) |
| Largest Undiagnosed Pool | Bronchiectasis: 300,000-500,000 US patients |
| Longest Diagnostic Delay | Bronchiectasis: 3-7 years |
| Best Symptom Fit | BRINSUPRI: Chronic productive cough + recurrent infections (highly specific) |
| Most Urgent Timing | BRINSUPRI: Launch year 2025; establish dominance before 2028-2029 competitor launches |
| Biggest Revenue Opportunity | BRINSUPRI: $175M-$513M lifetime PF revenue (10-year horizon) |